IFP Advisors
ZNTL icon

IFP Advisors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

IFP Advisors’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$69 Buy
+25
New +$101 ﹤0.01% 5027
2025
Q4 		– Sell
-24
Closed -$36 – 5057
2025
Q3 		$36 Sell
24
-11
-31% -$16 ﹤0.01% 4699
2025
Q2 		$40 Buy
+35
New +$46 ﹤0.01% 4813
2025
Q1 		– Sell
-23
Closed -$70 – 4672
2024
Q4 		$70 Buy
+23
New +$75 ﹤0.01% 4156
2022
Q4 		– Sell
-1,382
Closed -$42K – 4870
2022
Q3 		$42K Buy
1,382
+14
+1% +$383 ﹤0.01% 2512
2022
Q2 		$41K Hold
1,368
– – ﹤0.01% 2308
2022
Q1 		$41K Buy
1,368
+146
+12% +$7.88K ﹤0.01% 2306
2021
Q4 		$102K Buy
+1,222
New +$94.6K ﹤0.01% 1256

Other funds holding ZNTL

Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Evergreen Capital Management
Evergreen Capital Management Bellevue, Washington $5.65B AUM 21.62% 1-Year Est. Return
DLK Investment Management
DLK Investment Management Solana Beach, California $275M AUM 10.69% 1-Year Est. Return
Investment Research & Advisory Group
Investment Research & Advisory Group Atlanta, Georgia $337M AUM 19.8% 1-Year Est. Return
Sterling Capital Management
Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return
Nisa Investment Advisors
Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return
Fortitude Family Office
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
SBI Securities
SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return
Root Financial Partners
Root Financial Partners Encinitas, California $2.98B AUM 13.9% 1-Year Est. Return

IFP Advisors's ZNTL Position: Q3 2026 in Review

IFP Advisors opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q3 2026: 25 shares worth $69. The stake represents ﹤0.01% of the portfolio and ranks #5027 among its holdings. This is a return to the name: IFP Advisors previously reported a position in ZNTL as recently as Q3 2025.

IFP Advisors first reported a position in ZNTL in Q4 2021 and has held it in 8 quarters since. The position peaked at $102K in Q4 2021. 13 funds tracked by Wall St. Rank hold ZNTL as of Q3 2026.

  • IFP Advisors held 25 shares of Zentalis Pharmaceuticals worth $69 as of Q3 2026.
  • Zentalis Pharmaceuticals was a new IFP Advisors position in Q3 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q3 2026, its #5027 holding.
  • IFP Advisors first reported a position in Zentalis Pharmaceuticals in Q4 2021 and has held it in 8 quarters since.
  • IFP Advisors's Zentalis Pharmaceuticals position peaked at $102K in Q4 2021.
  • 13 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2026.

Based on IFP Advisors's 13F filing for Q3 2026, filed 16 Oct 2026.